CAREFUSION 8-K Results of Operations and Financial Condition

Exhibit 99.2

©

2013 CareFusion Corporation or one of its subsidiaries. All rights reserved.

Forward-Looking Statements

2

©

2013 CareFusion Corporation or one of its subsidiaries. All rights reserved.

“Safe

Harbor”

Statement

under

the

Private

Securities

Litigation

Reform

Act

of

1995:

This

presentation

contains

our

fiscal

2014

financial

guidance,

which

are

forward-looking

statements

addressing

expectations,

prospects,

estimates

and

other

matters

that

are

dependent

upon

future

events

or

developments.

The

matters

discussed

in

these

forward-looking

statements

are

subject

to

risks

and

uncertainties

that

could

cause

actual

results

to

differ

materially

from

those

projected,

anticipated

or

implied.

The

most

significant

of

these

uncertainties

are

described

in

CareFusion’s

Form

10-K,

Form

10-Q

and

Form

8-K

reports

(including

all

amendments

to

those

reports)

and

exhibits

to

those

reports,

and

include

(but

are

not

limited

to)

the

following:

we

may

be

unable

to

effectively

enhance

our

existing

products

or

introduce

and

market

new

products

or

may

fail

to

keep

pace

with

advances

in

technology;

we

are

subject

to

complex

and

costly

regulation;

cost

containment

efforts

of

our

customers,

purchasing

groups,

third-party

payers

and

governmental

organizations

could

adversely

affect

our

sales

and

profitability;

current

economic

conditions

have

and

may

continue

to

adversely

affect

our

results

of

operations

and

financial

condition;

we

may

be

unable

to

realize

any

benefit

from

our

cost

reduction

and

restructuring

efforts

and

our

profitability

may

be

hurt

or

our

business

otherwise

might

be

adversely

affected;

we

may

be

unable

to

protect

our

intellectual

property

rights

or

may

infringe

on

the

intellectual

property

rights

of

others;

defects

or

failures

associated

with

our

products

and/or

our

quality

system

could

lead

to

the

filing

of

adverse

event

reports,

recalls

or

safety

alerts

and

negative

publicity

and

could

subject

us

to

regulatory

actions;

and

we

are

currently

operating

under

an

amended

consent

decree

with

the

FDA

and

our

failure

to

comply

with

the

requirements

of

the

amended

consent

decree

may

have

an

adverse

effect

on

our

business.

This

presentation

reflects

management’s

views

as

of

August

8,

2013.

Except

to

the

limited

extent

required

by

applicable

law,

CareFusion

undertakes

no

obligation

to

update

or

revise

any

forward-looking

statements,

whether

as

a

result

of

new

information,

future

events

or

otherwise.

3

Fiscal 2014 Guidance         

August 8, 2013

FY14 Guidance

Total Revenue (constant currency)

1-4%

Medical Systems Revenue (constant currency)

1-4%

Procedural Solutions Revenue (constant currency)

2-4%

Adjusted Operating Margin¹

21-22%

Adjusted Effective Tax Rate¹

28-30%

Adjusted Diluted EPS From Continuing Operations¹

$2.30-$2.40

Diluted Weighted Average Shares Outstanding²

~215 million

Operating Cash Flow

$500-$550 million

Capital Expenditures

~$110 million

©

2013 CareFusion Corporation or one of its subsidiaries. All rights reserved.

1

Adjusted

amounts

are

non-GAAP

financial

measures.

These

measures

exclude

amortization

of

acquired

intangible

assets,

nonrecurring

restructuring

and

acquisition

integration

charges,

and

the

tax

effects

of

these

items.

A

GAAP

to

non-GAAP

reconciliation

can

be

found

in

the

company’s

Q4FY13

earnings

release,

which

was

furnished

to

the

SEC

on

Form

8-K

on

August

8,

2013

and

is

posted

on

CareFusion’s

website

at

www.carefusion.com

under

the

Investors

tab.

The

Form

8-K

also

includes

a

discussion

of

the

reasons

why

management

believes

that

the

presentation

of

non-GAAP

financial

measures

provides

useful

information

to

investors

regarding

the

company’s

financial

condition

and

results

of

operations.

2

On

August

8,

2013

CareFusion

announced

a

$750

million

share

repurchase

program.

Outlook

for

diluted

weighted

average

shares

outstanding

reflects

the

impact

of

expected

repurchases

during

fiscal

2014.

Conversion

markets provide

additional

growth

CFN markets

grow low

single digits

Base market

growth

M&A

Share gain

2012 Adjusted

Diluted EPS¹

2015 Adjusted

Diluted EPS¹

Margin mix

Operational

efficiencies

Revenue Growth

$1.95

$1B+ of

acquisition

spend

Operational

efficiency

initiatives

Mix shift to

higher margin

products

$1B+ share

repurchase²

12 -14%

CAGR

1

2012

Adjusted

Diluted

EPS

reflects

GAAP

EPS

of

$1.60

as

reported

in

the

Company’s

fiscal

2012

Form

10-K,

as

adjusted

for

nonrecurring

restructuring

and

acquisition

integration

charges

($0.16),

amortization

of

acquired

intangible

assets

($0.22),

spinoff

related

items

($0.02),

and

offset

by

the

tax

effect

of

these

items

($0.04).

As

EPS

calculations

are

performed

separately

for

each

component,

the

sum

of

the

per

share

components

may

not

equal

the

per

share

amounts

presented.

2

In

June

2013,

the

Company

completed

its

initial

$500

million

share

repurchase

authorization

announced

in

February

2012.

On

August

8,

2013

the

Company

announced

a

new

$750

million

share

repurchase

authorization.

Share

repurchases

in

excess

of

the

existing

authorization

are

subject

to

board

of

directors

approval.

Three year roadmap

4

Operating Margin

Expansion

Share

repurchase

©

2013 CareFusion Corporation or one of its subsidiaries. All rights reserved.